Shawn Tomasello Acquires 50,000 Shares of FDMT

Shawn Tomasello recently purchased 50,000 shares of FDMT on June 17, 2026. This transaction is part of a series of insider buys that day, reflecting interest from several insiders in the company's stock. FDMT shares were trading at $9.42 at the time of the purchase.

Other Institutional Activity in FDMT

Institutional investors have been actively adjusting their positions in FDMT. Janus Henderson Group PLC added 611,276 shares, bringing its total to approximately 5.25 million shares valued at about $48.87 million. Meanwhile, RA Capital Management, L.P. trimmed its holdings by 603,432 shares, ending with nearly 5.05 million shares worth approximately $47.01 million. Goldman Sachs Group Inc. slightly reduced its stake by 97,467 shares, holding about 4.21 million shares valued at $39.15 million. BlackRock, Inc. also increased its position by 80,427 shares, totaling around 4.15 million shares worth approximately $38.59 million.

4D Molecular Therapeutics, Inc. Stock Down 35.8%

Shares of FDMT were trading near $9.42. The stock has experienced a 52-week low of $5.00 and a high of $15.00, indicating a wide trading range over the past year. These price movements reflect ongoing interest and activity in the stock market.

Insider Buying and Selling at 4D Molecular Therapeutics, Inc.

On June 17, 2026, several insiders, including Charles Theuer, Glenn Sblendorio, Susannah Gray, John Milligan, Jacob Chacko, and Nancy Miller-Rich, each purchased 50,000 shares of FDMT. John Milligan acquired a larger stake of 75,000 shares. These purchases were not part of any pre-planned trading program, suggesting a direct interest in the company's prospects.

Analysts Set New Price Targets

Analysts maintain a positive outlook on FDMT. On March 30, 2026, Jefferies assumed coverage with a buy rating and a $21 price target. Earlier, HC Wainwright & Co. reiterated their buy rating with a $36 target on March 20, 2026. RBC Capital maintained its buy rating with a $35 target on March 19, 2026. Similarly, Chardan Capital kept its buy rating, setting a $26 target on the same day. Barclays initiated coverage with a buy rating and a $33 target on January 28, 2026.

About FDMT

FDMT is a company involved in the biotechnology industry. It focuses on developing innovative therapies to treat various diseases. The company is committed to advancing its research and development efforts to bring new treatments to market. Headquartered in the United States, FDMT continues to engage in significant scientific work to improve patient outcomes.

Bottom Line

Shawn Tomasello's purchase of 50,000 shares of FDMT on June 17, 2026, alongside other insider buys, highlights confidence in the company's future. Institutional investors have also been active, with some increasing their stakes while others have reduced theirs. Analysts remain optimistic, with several firms maintaining buy ratings and setting ambitious price targets. These activities suggest that FDMT is a stock to watch, though as always, past filings do not predict future performance.